Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

EUSA Pharma (UK) Ltd.

http://www.eusapharma.com/

Latest From EUSA Pharma (UK) Ltd.

Ligand Makes Second Big Oncology Investment In 2024 With Apeiron Buyout

The company is acquiring rights to royalties from Qarziba, a neuroblastoma drug approved in ex-US markets that Recordati develops and markets in all of them except mainland China.

Deals Cancer

Essential Emerges As A Drug Developer With Renaissance Buy

The acquisition of Renaissance and its promising Phase III-ready asset for neuroblastoma could be the first of a number of deals in the near future, Essential CEO Emma Johnson tells Scrip.

M & A Cancer

China’s Payer Keeps Deep Price Cuts Steady in Latest NRDL Listing

The 2022 pricing negotiations for innovative drugs organized by China’s National Healthcare Security Administration have slashed prices of included products by 60% on average, a level mostly unchanged from the 2021 round, although 36% more novel medicines were covered.

China Reimbursement

Recordati Expands Into Rare Cancer Space With EUSA Pharma Buy

The Italian company will acquire EUSA for €750m, helping to broaden its rare disease franchise into the oncology arena.

Companies Deals
See All

Company Information

  • Industry
  • Medical Devices
  • Pharmaceuticals
    • Specialty Pharmaceuticals
  • Biotechnology
    • Large Molecule
      • Antibodies
UsernamePublicRestriction

Register